{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Number of participants that had acute GVHD","groups":[{"description":"PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.","id":"OG000","title":"Arm I"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who went on study","reportingStatus":"POSTED","timeFrame":"At 100 days","title":"Incidence of Acute Graft-versus-host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"Participants"}